ESMO 2019 | Standard of care updates in ovarian cancer: PARP inhibitors
Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, speaks on the landmark trials from ESMO 2019 regarding PARP inhibitors in ovarian cancer. These trials include PRIMA (NCT02655016), PAOLA-1 (NCT02477644) and AURELIA (NCT00976911), which evaluate concurrent and maintenance therapy of combination treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Get great new content delivered to your inboxSign up